Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) have been assigned an average recommendation of “Moderate Buy” from the eleven analysts that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $42.4286.

A number of research analysts have recently weighed in on the stock. HC Wainwright assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Thursday, June 11th. They set a “buy” rating and a $45.00 price target on the stock. Guggenheim restated a “buy” rating and set a $40.00 price target (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. Royal Bank Of Canada assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Friday, April 24th. They set an “outperform” rating and a $40.00 price target on the stock. TD Cowen assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, June 8th. They set a “buy” rating on the stock. Finally, Evercore assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Wednesday, March 25th. They issued an “outperform” rating and a $46.00 target price on the stock.

Damora Therapeutics, Inc. Common Stock Trading Up 2.6%

Damora Therapeutics, Inc. Common Stock stock opened at $20.59 on Friday. The company has a market capitalization of $1.27 billion, a P/E ratio of -3.69 and a beta of 1.46. The firm’s fifty day simple moving average is $24.31 and its 200-day simple moving average is $25.45. Damora Therapeutics, Inc. Common Stock has a 1-year low of $2.45 and a 1-year high of $38.33.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). On average, equities research analysts predict that Damora Therapeutics, Inc. Common Stock will post -1.92 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Ikarian Capital LLC bought a new position in Damora Therapeutics, Inc. Common Stock in the 4th quarter worth $6,574,000. Janus Henderson Group PLC bought a new position in Damora Therapeutics, Inc. Common Stock in the 4th quarter worth $40,000. Boothbay Fund Management LLC bought a new position in Damora Therapeutics, Inc. Common Stock in the 4th quarter worth $2,204,000. Jain Global LLC bought a new position in Damora Therapeutics, Inc. Common Stock in the 4th quarter worth $2,774,000. Finally, Remedium Capital Partners LLC bought a new position in Damora Therapeutics, Inc. Common Stock in the 4th quarter worth $2,772,000. Institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.